TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Immunocore Holdings Plc
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

Immunocore announced Phase 1 trial results for IMC-I109V, a T cell receptor bispecific candidate targeting hepatitis B virus, showing promising dose-dependent HBsAg reduction and a generally manageable safety profile.

Insights
IMCR   positive

Positive trial results demonstrating potential efficacy and safety of IMC-I109V, with dose-dependent HBsAg reduction and manageable adverse events